Secretin synthetic human
Chirhostim (secretin synthetic human) is a protein pharmaceutical. Secretin synthetic human was first approved as Secretin-ferring on 1982-01-01. The pharmaceutical is active against secretin receptor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Chirhostim
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| chirhostim chirhostim 40 | New Drug Application | 2021-10-14 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
34 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatitis | D010195 | EFO_0000278 | K85 | 1 | 1 | 1 | 1 | 1 | 5 |
| Sphincter of oddi dysfunction | D046628 | — | — | — | 1 | — | 1 | ||
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 1 | 1 | — | 6 | 9 |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | — | 3 | — | — | 3 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | 1 | — | 1 | 2 |
| Peutz-jeghers syndrome | D010580 | Q85.89 | — | — | 1 | — | 1 | 2 | |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | — | 1 | — | — | 1 |
| Abdominal pain | D015746 | R10.9 | — | — | 1 | — | — | 1 | |
| Hereditary nonpolyposis colorectal neoplasms | D003123 | EFO_0007354 | — | — | 1 | — | — | 1 | |
| Pancreatic diseases | D010182 | K86.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic pancreatitis | D050500 | EFO_0000342 | K86.1 | 5 | 2 | — | — | — | 5 |
| Healthy volunteers/patients | — | 1 | 1 | — | — | 1 | 2 | ||
| Dyspepsia | D004415 | EFO_0008533 | K30 | 1 | 1 | — | — | — | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | — | — | — | 1 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic intraductal neoplasms | D000077779 | 1 | — | — | — | 1 | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | — | — | — | 1 | 1 |
| Adiposity | D050154 | — | — | — | — | 1 | 1 | ||
| Endoscopic retrograde cholangiopancreatography | D002760 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SECRETIN SYNTHETIC HUMAN |
| INN | — |
| Description | Secretin precursor |
| Classification | Protein |
| Drug class | retinol derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 108153-74-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201488 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 35 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more